The basis on which India approves precaution dose remains unclear
He said the primary focus of the government was on giving a second dose of the vaccine to make people fully vaccinated. “Administering the second dose of COVID-19 vaccine to…
Category: Neutralizing antibodies
Covaxin elicits immune memory to virus up to six months, study finds
The study has been posted on a preprint server medRxiv. Preprints are yet to be peer-reviewed and published in a scientific journal. The multi-institutional research, which is led by a…
Study finds Covishield produces more antibodies than Covaxin, but scientists point out serious flaws with the preprint
The seropositivity rates and the median antibody titre against spike protein was “significantly higher” in those vaccinated with Covishield compared with Covaxin, according to a preprint posted in medRxiv. Preprints…
Covaxin offers protection against double mutant (B.1.617) variant
A preprint of the study carried out by ICMR and Bharat Biotech researchers has been posted in biorXiv. Preprints are yet to be peer-reviewed and published in medical journals. So…
COVID-19: Protection against reinfection may last only for months
The first serosurvey was carried out in August-September 2020 and the six-month follow-up was carried out in end-January to February 2021. Widespread asymptomatic infection by mid-September when the daily cases…
Moderna, Pfizer vaccines neutralise variants encoding mutations E484K or N501Y but with less potency
The results were published in the journal Nature. Both Moderna and Pfizer-BioNTech vaccines showed no significant difference in neutralising activity. Individuals immunized with either Moderna or Pfizer-BioNTech vaccines produce closely…
Oxford vaccine found safe and immunogenic even in older adults
The results were published online in The Lancet on November 19. The results are based on the study of 560 participants enrolled between May 30 and August 8. Of the…
Pre-existing memory T cells may reduce COVID-19 severity, but do not prevent infection
Pre-existing memory T cells that cross-react with SARS-CoV-2 may only reduce COVID-19 severity cannot prevent infection. The memory T cells are extremely unlikely to prevent SARS-CoV-2 infections. That is just…
Science Chronicle 